Peloton Therapeutics raises USD 150 Million for treating Advance Kidney Cancer
Peloton Therapeutics has been in the process of developing small molecule drugs to treat Cancer, has raised USD 150 million. Peloton’s lead therapeutic candidate, PT2977, focuses on targeting hypoxia-inducible factor-2a, or HIF-2a, in Renal cell carcinoma. The drug has probable chances for treatment of Von Hippel-Lindau disease, a genetic cancer syndrome which at present has no approved drugs.
BiomX raises USD 32 Million to eliminate bacteria
BiomX has netted USD 32 million to eliminate the existence of bacteria causing Acne and Inflammatory bowel disease. The treatment as of now is in pre-clinical trials. The bacteriophage, in development, stays active against antibiotic-resistant strains of Propionibacterium acnes leaving the others present in the skin. In addition, it has the ability to replicate itself producing up to 100 more from each bacteria it destroys.
Abbott and Novo Nordisk collaborate to assist Diabetic patients
Abbott and Novo Nordisk entered into a non-exclusive agreement to incorporate insulin dose data from Novo Nordisk prefilled and durable pens into the digital health tools compatible with the FreeStyle Libre system. The alliance is keen on making Diabetes management simpler. It linked key technologies such as continuous glucose monitoring (CGM) and connected insulin pens. So, this will help the affected people to study their glucose and insulin data together. It will help in making more informed treatment decisions.
Blaze Bioscience nets USD 5 Million to detect tumor cells
Blaze Bioscience, Seattle-based biotech has raised USD 5 Million to develop a ‘TUMOR PAINT’ that can differentiate tumor cells from the normal ones. BLZ-100-Blaze’s main product is a fluorescent imaging agent. It is injected intravenously in Cancer patients before the operation begins. Therefore, it helps surgeons to easily identify them.